Skip to main content
Back
Watch Compare

Altimmune, Inc.

Data quality: 100%
ALT
Nasdaq Manufacturing Chemicals
$3.36
▼ $0.02 (-0.45%)
Mkt Cap: 436.50 M
Price
$3.36
Mkt Cap
436.50 M
Day Range
$3.31 — $3.38
52-Week Range
$2.87 — $7.73
Volume
965,594
Open $3.37
50D / 200D Avg
$4.20
20.11% below
50D / 200D Avg
$4.21
20.27% below

Quick Summary

Key Takeaways

Revenue declined -68.95% annually over 5 years
Debt/Equity of 0.08 — conservative balance sheet
Negative free cash flow of -67.55 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 173.95%

Growth

Revenue Growth (5Y)
-68.95%
Below sector avg (1.82%)
Revenue (1Y)105.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-50.78%
Above sector avg (-53.41%)
ROIC-38.58%
Net Margin-214860.98%
Op. Margin-230460.98%

Safety

Debt / Equity
0.08
Below sector avg (0.31)
Current Ratio17.18
Interest Coverage-57.76

Valuation

PE (TTM)
-4.96
Below sector avg (-1.48)
P/B Ratio2.35
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -5.0 -1.5
P/B 2.4 1.6
ROE % -50.8 -53.4
Net Margin % -214861.0 -41.5
Rev Growth 5Y % -69.0 1.8
D/E 0.1 0.3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0.41% weight
FSCC logo FSCC Federated Hermes MDT Small Cap Core ETF
0.27% weight
DLHIX DLHIX
0.05% weight
DLHAX DLHAX
0.05% weight
DLRHX DLRHX
0.05% weight
AVSU logo AVSU Avantis Responsible U.S. Equity ETF
0.00% weight
IWV logo IWV iShares Russell 3000 ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 105.00% Revenue Growth (3Y) -68.98%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -68.95% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 41,000.0 Net Income (TTM) -88.09 M
ROE -50.78% ROA -43.10%
Gross Margin N/A Operating Margin -230460.98%
Net Margin -214860.98% Free Cash Flow (TTM) -67.55 M
ROIC -38.58% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.08 Current Ratio 17.18
Interest Coverage -57.76 Asset Turnover 0.00
Working Capital 204.01 M Tangible Book Value 185.60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.96 Forward P/E N/A
P/B Ratio 2.35 P/S Ratio 10646.41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15.47%
Market Cap 436.50 M Enterprise Value 389.71 M
Per Share
EPS (Diluted TTM) -1.00 Revenue / Share 0.00
FCF / Share -0.52 OCF / Share -0.52
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 26.83% FCF Conversion 76.68%
SBC-Adj. FCF -81.76 M Growth Momentum 173.95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 41,000.0 20,000.0 426,000.0 -68,000.0 4.41 M
Net Income -88.09 M -95.06 M -88.45 M -84.71 M -97.09 M
EPS (Diluted) -1.00 -1.34 -1.66 -1.81 -2.35
Gross Profit — — — — —
Operating Income -94.49 M -103.17 M -95.93 M -87.74 M -96.91 M
EBITDA — — — — —
R&D Expenses 66.43 M 82.23 M 65.80 M 70.54 M 74.54 M
SG&A Expenses — — — — —
D&A — — — — 551,301.0
Interest Expense 1.64 M 9,000.0 35,000.0 8,000.0 5,656.0
Income Tax -681,000.0 — -197,000.0 -197,000.0 -5.42 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 279.93 M 139.31 M 210.64 M 206.93 M 218.86 M
Total Liabilities 55.04 M 15.80 M 16.54 M 21.64 M 19.73 M
Shareholders' Equity 224.89 M 123.51 M 194.10 M 185.29 M 199.13 M
Total Debt 34.29 M — — 4.58 M 1.45 M
Cash & Equivalents 43.76 M 36.93 M 135.12 M 111.10 M 190.30 M
Current Assets 278.19 M 137.25 M 209.63 M 192.81 M 204.13 M
Current Liabilities 15.00 M 10.47 M 12.14 M 17.05 M 18.28 M